Printed from Voxsanity (voxsanity.com.au) — NCT03832127 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Myeloma
Phase 1 Myeloma Trial, Recruiting
NCT03832127
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with multiple myeloma (a type of blood cancer) who are starting their first treatment and are not suitable candidates for a stem cell/bone marrow transplant using their own cells
- People whose treatment plan matches one of the standard treatments recommended by European cancer guidelines (ESMO) for patients who cannot have a transplant
- People whose multiple myeloma can be measured through blood or urine tests that detect abnormal proteins produced by the cancer
- People who are covered by a social insurance (healthcare) scheme
- People who are willing and able to read and sign a consent form agreeing to take part
- Women who could become pregnant must have a blood pregnancy test done within 2 days before each PET scan (a type of imaging scan used in this trial)
- Women who could become pregnant must use an effective form of contraception throughout the trial and for 30 days after the last PET scan
- Male participants (whether or not they have had a vasectomy) whose partner is pregnant or could become pregnant must use a condom and spermicide until 90 days after the last PET scan
- People with a confirmed negative HIV test result
- People who are in reasonably good general health, as measured by standard medical scoring scales (Karnofsky score of 70 or above, or ECOG score of 0–1) (confirm with trial site)
Who may not be able to join:
- People under 18 years of age
- People who are pregnant or breastfeeding
- People who are unwilling to follow the required contraception conditions
- People who have a condition called AL amyloidosis, or multiple myeloma complicated by amyloidosis (a related protein-buildup condition)
- People with a low white blood cell count (neutropenia below a certain level)
- People with a low platelet count (platelets are cells that help blood clot), below a certain level
- People with significant liver problems, indicated by elevated levels of certain liver-related substances in the blood
- People with significant kidney problems, where kidney filtering function falls below a certain level
- People who have had another type of cancer in the past, with the exception of a specific type of skin cancer (basal cell carcinoma) or early-stage cervical cancer
- People with a serious active infection
- People with an active hepatitis B or hepatitis C infection
- People with diabetes, whether managed with insulin or other treatments
- People with a known allergy or intolerance to any of the medications used in this trial or similar medications
- People with a psychiatric condition that may affect their ability to take part in the trial
- People who are under a legal protection order or guardianship arrangement
- People who are not able to understand or sign a consent form
- People who are protected under specific legal provisions (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 33240084136
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
9 September 2022
Est. completion
9 September 2024
Where this trial is recruiting
🇫🇷 France
Primary endpoints
Detection of sensitivity of the lesions (osseous and extra-osseous) of 18Fludarabine PET (FludaTEP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.